Related Experiment Video

Updated: Sep 17, 2025

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.1K

SKP2 E3 ligase in urological malignancies: a critical regulator of the cell cycle and therapeutic target

Mohannad Natheef AbuHaweeleh1, Lubna Therachiyil2, Kirti S Prabhu2

  • 1College of Medicine, Qatar University, Doha, Qatar.

Cell Cycle (Georgetown, Tex.)
|July 3, 2025
PubMed

Insights

SKP2 overexpression drives urological cancers by promoting cell cycle progression and tumor growth. Targeting SKP2 offers a promising therapeutic strategy for prostate, bladder, and kidney cancers.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • SKP2 (S-phase kinase-associated protein 2) is an E3 ubiquitin ligase crucial for cell cycle regulation.
  • It targets cell cycle inhibitors like p27, p21, and p57 for degradation, facilitating the G1-S phase transition.
  • Overexpression of SKP2 is linked to aggressive urological malignancies and poor patient outcomes.

Purpose of the Study:

  • To elucidate the role of SKP2 in the progression of urological cancers.
  • To explore the therapeutic potential of targeting SKP2 in prostate, bladder, and kidney cancers.

Main Methods:

  • Review of existing literature on SKP2 function and its association with urological malignancies.
  • Analysis of SKP2's role in cancer cell proliferation, invasion, and metastasis.
  • Discussion of therapeutic strategies targeting SKP2.

Main Results:

  • SKP2 overexpression is a significant driver of tumor progression in urological cancers.
  • It enhances cancer cell proliferation, invasion, and metastasis.
  • Targeting SKP2 presents a promising therapeutic avenue.

Conclusions:

  • SKP2 is a critical oncogene in urological cancers, promoting tumor growth and progression.
  • Targeting SKP2 via small molecule inhibitors or combination therapies holds therapeutic promise.
  • Further research is needed to address challenges in targeting SKP2 for personalized urological cancer medicine.
Keywords:
CancerE3 ubiquitinSKP2cell cyclep21urological cancer

More Related Videos

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols12:02

Studying Cell Cycle-regulated Gene Expression by Two Complementary Cell Synchronization Protocols

Published on: June 6, 2017

27.7K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

11.5K

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.9K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
36.1K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K